Many patients suffer not only from respiratory symptoms due to their COVID-19 disease, but also from significantly reduced physical performance. A patent-protected tablet (CICR-NAM) developed at the ...

In high-risk patients with COVID-19, nirmatrelvir/ritonavir treatment shortened the median duration to return to usual health and activities and significantly accelerated the resolution of COVID-19 ...

Researchers have tested a novel therapeutic concept to treat virus-induced lung failure in patients with severe COVID-19 in a phase 2 clinical trial. The approach may also be applicable to other ...

Brazilian researchers reveal that even mild cases of COVID-19 can temporarily reduce heart rate variability, with stress on the autonomic nervous system lasting up to six months—especially in older ...

How the body responds to COVID-19 will vary from one person to the next, and the same goes for the recovery period from the virus. How long it’ll take to recover from COVID-19 is always going to be ...

Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City, reflects on how the reality of COVID-19 ...

Paxlovid (nirmatrelvir-ritonavir) does not reduce hospital admissions or deaths in vaccinated adults at higher risk of severe COVID-19, despite helping them recover faster, according to results from ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...